Price Alert

AbbVie Inc. (ABBV)

NYSE: ABBV · Real-Time Price · USD

219.87

-0.35 (-0.16%)

At close: Sep 12, 2025, 2:01 PM

-0.16% (1D)

Bid	219.81
Market Cap	388.41B
Revenue (ttm)	58.33B
Net Income (ttm)	3.77B
EPS (ttm)	2.1
PE Ratio (ttm)	104.7
Forward PE	14.86
Analyst	Buy

Ask	219.95
Volume	1,789,993
Avg. Volume (20D)	5,507,961
Open	219.12
Previous Close	220.22
Day's Range	218.24 - 220.36
52-Week Range	163.81 - 221.77
Beta	0.53

About ABBV

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ABBV

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ABBV stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

AbbVie Inc. is scheduled to release its earnings on Oct 29, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 day ago New

+4.05%

AbbVie shares are trading higher after the company... Unlock content with Pro Subscription

1 month ago

+3.28%

AbbVie shares are trading higher after Morgan Stanley and Guggenheim raised their respective price targets on the stock.

News

Just now · zacks.com

AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock

ABBV secures Rinvoq's market lead until 2037, boosting shares as strong sales and new indications fuel long-term growth prospects.

Just now · barrons.com

AbbVie Stock Hit a Record on ‘Big Win' for Blockbuster Drug. The Case for Buying In.

The company is dealing with declining sales of its former cash-cow drug Humira.

1 day ago · proactiveinvestors.com

AbbVie shares rise with extension of RINVOQ patent protection to 2037

Abbvie Inc (NYSE:ABBV) shares moved higher after the pharma company announced it has secured extended patent protection for its blockbuster autoimmune drug RINVOQ (upadacitinib). It said in a regulato...

19 hours ago · reuters.com

AbbVie shares hit record high as key immunology drug set for exclusivity until 2037

AbbVie shares rose 4% to a record high on Thursday after the U.S. drugmaker said it expected no generic competition for its blockbuster immunology drug Rinvoq until 2037, a four-year extension, accord...

19 hours ago · wsj.com

AbbVie in Settlement With Generic Drugmakers on Rinvoq

The biopharmaceutical company doesn't expect U.S. generic entry for the drug before 2037 now that it has settled litigation.

20 hours ago · fool.com

Why AbbVie Stock Is Jumping Today

Shares of AbbVie (ABBV 3.95%) were jumping 4.2% higher as of 11:37 a.m. ET on Thursday.

22 hours ago · zacks.com

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

22 hours ago · benzinga.com

Why Is AbbVie Stock Trading Higher On Thursday?

AbbVie Inc. ABBV stock is trading higher on Thursday following an SEC filing that settled litigation with all generic manufacturers, which filed abbreviated new drug applications with the U.S. Food an...

22 hours ago · forbes.com

AbbVie: What's Happening With ABBV Stock?

AbbVie's stock is on the rise, and for good reason! The company just reached a major agreement with generic drug manufacturers to delay the release of a generic version of its blockbuster drug, Rinvoq...

3 days ago · seekingalpha.com

AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

AbbVie Inc. (NYSE:ABBV ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:00 AM EDT Company Participants Robert Michael - CEO & Chairman of the Board Jeffrey Stewart - Exec...

Load More News